Merck KGaA (MRK) AI Stock Analysis

• Market Cap: €45.24B
• Dividend Yield: 1.82%
• Average Volume (3M): 321.00K
• Price to Earnings (P/E): 20.4
• Beta (1Y): 0.94
• Revenue Growth: 1.47%
• EPS Growth: 9.64%
• Country: DE
• Employees: 59,020
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.88
• Shares Outstanding: 129,242,250
• 10 Day Avg. Volume: 344,164
• 30 Day Avg. Volume: 321,004
• PEG Ratio: -3.35
• Price to Book (P/B): 1.86
• Price to Sales (P/S): 2.53
• P/FCF Ratio: 22.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €139.86
• Price Target Upside: 34.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): 7.7
• Revenue Forecast (FY): €20.89B

• Rating: 58 Neutral
• Price Target: €115.00 ▲(10.52% Upside)
• Action: Downgraded Date: 03/07/26
• Date: Action: Downgraded 03/07/26

The score is led by solid underlying profitability and a sound balance sheet, but it is pulled down by a pronounced bearish technical setup (price below key moving averages and negative MACD). Valuation is moderate with a ~2% yield, offering some support but not enough to offset weakening recent growth and momentum.

Positive Factors

Diversified business model

Merck's multi-segment footprint across pharmaceuticals, life‑science tools and performance materials provides diversified revenue streams and reduces dependence on any single product cycle. That structural diversity supports steadier cash flows and resilience across economic or industry-specific downturns over the next several months.

Strong structural margins

Sustained gross and EBITDA margins in the mid‑50s/low‑60s and high‑20s respectively indicate durable pricing power and operational efficiency across businesses. These margin levels support ongoing R&D investment, dividend capacity and the ability to absorb cost headwinds without immediate damage to core earnings power.

Sound balance sheet and positive FCF

A reasonable leverage profile and sizable equity base provide financial flexibility for capital allocation, while consistently positive free cash flow (with a notable step‑up in 2025) supports funding for R&D, M&A and shareholder returns. This combination enhances resilience and strategic optionality over the medium term.

Negative Factors

Recent top-line weakness

Revenue declined in 2025 after a 2024 rebound, reflected in a negative revenue growth metric. Prolonged or recurring top‑line weakness can reduce operating leverage, constrain reinvestment and slow pipeline commercialization, making it harder to sustain prior growth rates over the next several quarters.

Eroding net margins

Net margins have drifted down from earlier peaks, signaling pressure on bottom‑line profitability. Persistent margin erosion may reflect pricing pressure, cost inflation or product mix shifts, and reduces free cash generation and reinvestment capacity, undermining durable earnings recovery prospects.

Inconsistent cash conversion

While free cash flow is positive, cash conversion has been inconsistent and operating cash flow was notably weaker in 2025. Irregular cash conversion increases forecasting risk, can constrain discretionary spending or deleveraging plans, and complicates capital allocation decisions over the medium term.

Merck KGaA Business Overview & Revenue Model

Company Description

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

How the Company Makes Money

Merck KGaA generates revenue through multiple streams including the sale of pharmaceuticals and biopharmaceuticals, which represent a significant portion of its income. The healthcare segment focuses on innovative medicines and biosimilars, while the life science sector provides laboratory products and services to research and academic institutions. Additionally, the performance materials division contributes revenue through specialty chemicals and materials for the electronics and cosmetics industries. The company also benefits from strategic partnerships and collaborations, which enhance its product offerings and market reach. Furthermore, ongoing investments in research and development enable Merck KGaA to innovate and expand its product pipeline, thereby driving future revenue growth.

Merck KGaA Financial Statement Overview

Summary

Profitability is solid (gross margin mid‑50s to low‑60s; EBITDA margin ~27–30%), and the balance sheet is sound with moderate leverage. Offsetting this, revenue declined in 2025 after a 2024 rebound, net margins have drifted down from 2021–2022 peaks, and cash conversion/operating cash flow have been inconsistent despite positive free cash flow.

Income Statement

Merck KGaA shows solid profitability with gross margins generally in the mid‑50% to low‑60% range and EBITDA margins holding near ~27–30% over 2020–2025. However, growth has been inconsistent: revenue rebounded in 2024 but fell back in 2025, and net margin has trended lower versus the 2021–2022 peak. Overall, earnings power remains healthy, but the recent top-line softness and margin compression temper the score.

Balance Sheet

The balance sheet looks sound with moderate leverage: debt-to-equity improved materially versus 2020 and remains reasonable despite a debt increase in 2025. Equity and total assets are sizable, supporting financial flexibility. Return on equity is positive and stable but has cooled from earlier highs, suggesting slightly less efficient profitability on the current capital base.

Cash Flow

Cash generation is positive, with free cash flow consistently positive across the period and a strong step-up in free cash flow growth in 2025. That said, free cash flow has not consistently tracked earnings closely (free cash flow running at roughly half to two‑thirds of net income), and operating cash flow has been choppy (notably lower in 2025 versus 2024). The business generates cash, but conversion and consistency are the main weaknesses.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	21.10B	21.16B	20.99B	22.23B	19.69B
Gross Profit	11.89B	11.95B	11.67B	12.84B	11.60B
EBITDA	5.95B	6.17B	5.83B	6.79B	5.99B
Net Income	2.61B	2.78B	2.82B	3.33B	3.06B
Balance Sheet
Total Assets	52.10B	51.57B	48.49B	48.53B	45.36B
Cash, Cash Equivalents and Short-Term Investments	2.74B	2.71B	2.41B	1.64B	1.62B
Total Debt	11.97B	10.27B	9.94B	10.40B	10.77B
Total Liabilities	23.44B	21.58B	21.74B	22.52B	23.95B
Stockholders Equity	28.59B	29.91B	26.68B	25.93B	21.34B
Cash Flow
Free Cash Flow	2.35B	2.40B	1.76B	2.45B	3.19B
Operating Cash Flow	3.93B	4.59B	3.78B	4.26B	4.62B
Investing Cash Flow	-4.26B	-3.05B	-1.89B	-2.74B	-1.58B
Financing Cash Flow	628.00M	-985.00M	-1.73B	-1.55B	-2.50B

Merck KGaA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 104.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MRK, the sentiment is Negative. The current price of 104.05 is below the 20-day moving average (MA) of 115.60, below the 50-day MA of 122.20, and below the 200-day MA of 115.58, indicating a bearish trend. The MACD of -4.83 indicates Positive momentum. The RSI at 28.41 is Positive, neither overbought nor oversold. The STOCH value of 20.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:MRK.

Merck KGaA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FRE	62 Neutral	€24.36B	19.40	7.50%	2.05%	0.63%	―
MRK	58 Neutral	€45.24B	20.44	10.32%	1.82%	1.47%	9.64%
SHL	57 Neutral	€40.78B	27.87	11.65%	2.13%	4.53%	10.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BIO	51 Neutral	€1.35B	-58.47	4.98%	―	-18.82%	-113.85%
SRT	49 Neutral	€12.80B	110.19	5.77%	0.39%	5.82%	59.90%
BAYN	48 Neutral	€37.71B	-10.04	-12.24%	0.31%	-1.87%	77.51%